

FOR IMMEDIATE RELEASE

Contact: Sandra Richards  
Great Basin Scientific, corporate communications  
801.979.1077

**GREAT BASIN SCIENTIFIC, INC. ANNOUNCES PATENT  
FILING FOR INNOVATIVE MOLECULAR DIAGNOSTICS TECHNOLOGY**

*Leading Life Sciences Research Firm Leverages Human Genome Project Success to Enhance Intellectual Property Portfolio with New Technology for Rapid Diagnosis of Genetic Conditions and Diseases*

**LAS VEGAS, Nevada — July 3, 2006** — Great Basin Scientific today announced the filing of a patent application related to a new highly sensitive technology for molecular diagnostics that will allow for the rapid diagnosis of genetic conditions and diseases without polymerase chain reaction (PCR) or other costly amplification systems. The technology, which the company plans to have productized by mid to late 2007, is targeted to the rapid, point-of-care (POC) genetic screening market. This new patent application follows on the heels of two previous patent applications—filed by Great Basin in December of 2005—related to enhanced sensitivity and capabilities of the company’s rapid molecular test platform. The technologies covered by these patent filings significantly strengthen the Company’s patent portfolio, positioning the company to take a leadership position in the POC testing and diagnostic products market.

“The Human Genome Project is providing a wealth of genomic discoveries that have the potential to revolutionize how we diagnose and treat genetic conditions and diseases,” said David C. Ward, PhD, founder of Great Basin Scientific. “Great Basin’s core objective—as evidenced by our aggressive intellectual property development efforts—is to unlock the potential of these discoveries by delivering cost-effective genetic screening tools with broad array of commercial opportunities.”

Trimark Publications, a leading research firm in the human diagnostics field, estimates that the market for genetic testing will grow to \$12 billion by 2010, up from \$3.1 billion in 2000. Ryan Ashton, CEO and president, Great Basin Scientific, concluded, “Moving access to these tests from the reference lab—with the associated high costs and long turnaround for results—to the point-of-care market, will a critical driver of this

explosive growth. Our growing portfolio of groundbreaking intellectual property is providing a strong foundation for the development of Great Basin's first-phase commercial products, giving us the ability to deliver point-of-care genetic screening technology that will be simple to use, fast, and inexpensive. Great Basin is making genetic screening, diagnosis and treatment products that will allow us to successfully develop products and partnerships to attack this fast-growing market.”

### **About Great Basin Scientific**

Founded in 2003 Great Basin Scientific, Inc. is dedicated to developing state-of-the-art technology and products that will improve automation, throughput, scalability and reliability of in-house rapid diagnostic testing for use by health care providers. GBS is based in Las Vegas, Nevada, with research laboratories in Nevada and Utah.

###